Falk Foundation | Dr. Falk
You are here:  About usCompanyInnovation and Partnering
Innovation and Partnering

Dr. Falk Pharma is a leading pharmaceutical company specializing in gastroenterology and hepatology. Our vision is founded on generating and sharing the knowledge that drives innovation, with the goal of improving patients’ lives through the development of novel therapeutics for gastrointestinal and hepatic diseases.

Together with our trusted partners, we are continuously pursuing transformative ideas and advances that can be translated into innovative treatments.

These projects can originate from any promising pharmacological concept – from small molecules to biologics – and any stage of development, and may come from academic researchers, clinical practitioners, startups, or established companies.

Dr. Falk Pharma is an industry leader in innovative pharmaceutical formulations ensuring targeted release of active substances at specific sites of gastrointestinal diseases. Many of our products have attained standard-of-care status.

We enjoy an excellent reputation among academic and clinical key opinion leaders in the fields of gastroenterology and hepatology, resulting in strong, long-standing collaborations with renowned clinical centers.

As a partner, we offer comprehensive expertise across the entire value chain ranging from pharmaceutical, non-clinical and clinical development to regulatory approval, manufacturing, and marketing.
If you would like to discuss a partnering project with us, you can meet us at the relevant partnering events, reach out to one of our local affiliates, or contact us directly by e-mail to

Dirk Brehmer – Head of Scientific Innovation, Gastroenterology and Hepatology,

Patienten für laufende Studie zu MORBUS CROHN gesucht!

Klinische Studie zur Beurteilung eines neuen, sich in der Erprobung befindlichen biologischen Medikaments. Der Name der Studie ist TRUST-2, was für „TRichUris Suis ova Trial“ steht.

Mehr als 200 Patienten mit MORBUS CROHN haben das sich in der Erprobung befindende Studienmedikament bisher in klinischen Studien eingenommen.

Die Studien zeigen eine Abnahme der Krankheitsaktivität und in der Mehrzahl der Fälle wurde Remission (beschwerdefreie Phase) erzielt. Die bisher beobachteten Nebenwirkungen betrafen zumeist den Verdauungstrakt.